Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282234 | 1.00 | MEN1 (0.57) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL1421530 | 1.00 | MEN1 (0.57) | MEN1KMT2ALMNATSHRHTT | |
| Oxalic Acid SCHEMBL16649321 | 0.96 | MEN1 (0.54) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL6169592 | 0.90 | CA2 (0.56) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL6169593 | 0.90 | CA2 (0.56) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL8758435 | 0.84 | KIF11 (0.49) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL13890445 | 0.84 | MEN1 (0.61) | MEN1KMT2ALMNATSHRHTT | |
| SCHEMBL133675 | 0.84 | KIF11 (0.49) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL7717526 | 0.84 | KIF11 (0.49) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| SCHEMBL7089012 | 0.82 | CA12 (0.47) | MEN1KMT2ALMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081907-A | Radiolabeled bombesin derivative compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2025-06-03 | — | — | CN | claimed |
| CN-118812647-A | Novel insect short neuropeptide sNPF analogue and application thereof | 四川轻化工大学 | 2024-10-22 | — | — | CN | claimed |
| CN-118104562-A | High-yield seed production method for peppers | 遵义市农业科学研究院 | 2024-05-31 | — | — | CN | claimed |
| EP-3374520-A1 | BIOSENSORS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-09-19 | — | — | EP | claimed |
| WO-2017081684-A1 | BIOSENSORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-18 | — | — | WO | claimed |
| US-7538245-B2 | Process for the manufacture of an enantiopure compound | SOLVAY S.A. (BE) | 2009-05-26 | — | — | US | claimed |
| US-20070027326-A1 | Process for the manufacture of an enantiopure compound | SOLVAY S.A. (BE) | 2007-02-01 | — | — | US | claimed |
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | claimed |
| EP-1664084-A1 | PROCESS FOR THE MANUFACTURE OF AN ENANTIOPURE COMPOUND | SOLVAY (Société Anonyme) (BE) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023838-A1 | PROCESS FOR THE MANUFACTURE OF AN ENANTIOPURE COMPOUND | Solvay (Société Anonyme) (BE) | 2005-03-17 | — | — | WO | claimed |
| CN-1387567-A | Conjugates between peptides and nucleic acid analogues such as PNA, LNA, or morpholino | PANTHECO AS (DK) | 2002-12-25 | — | — | CN | claimed |
| EP-1046627-A2 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (Société Anonyme) (BE) | 2000-10-25 | — | — | EP | claimed |
| US-5952346-A | INHIBITS THE ACTIONS OF THE ALZHEIMER'S PROTEIN AMYLOID (BETA/A4) IN ISOLATED ENDOTHELIAL CELLS; QUINOLINE DERIVATIVES | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 1999-09-14 | — | — | US | claimed |
| WO-1998010786-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYNDROME X OF REAVEN | COHEN YAROM (IL) | 1998-03-19 | — | — | WO | claimed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | claimed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | claimed |
| EP-0203031-B1 | BIOLOGICALLY ACTIVE LYSINE CONTAINING OCTAPEPTIDES | The Administrators of The Tulane University Educational Fund (US) | 1992-07-29 | — | — | EP | claimed |
| WO-1992007845-A1 | DERIVATIVES OF AMINO ACIDS AS INHIBITORS OF RENIN, METHODS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-14 | — | — | WO | claimed |
| EP-0483403-A1 | Derivatives of amino acids as inhibitors of renin, methods for their preparation, medicaments containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-06 | — | — | EP | claimed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027326-A1 | Process for the manufacture of an enantiopure compound | AMD1, DAO, DDC | MEN1 3808/4885KMT2A 3516/4885LMNA 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.